Jci_page_head_homepage_01 Jci_page_head_homepage_02
Jennifer L. Gommerman, Fabienne Mackay, Elina Donskoy, Werner Meier, Pauline Martin, Jeffrey L. Browning
Published in Volume 110, Issue 9
J Clin Invest. 2002; 110(9):1359–1369 doi:10.1172/JCI15975
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 5

LTβR-Ig treatment results in changes in the splenic MZ. Spleens from untreated (a, c, e, g) and treated (8 mg/kg LTβR-Ig) animals (b, d, f, h) were stained with Asm-1 (red) and anti-IgD (green) (a, b), or stained with Asm-1 (red) and anti-VCAM-1 (green) (cf), or stained with anti-IgD (green) with anti–VCAM-1 (green) (gh). The i-MZ is identified (a) with arrows. The Asm-1/VCAM-1–positive MZ is identified (c, e, g) with arrows. Representative spleens were examined by fluorescence microscopy and were photographed at ×100 (a, b, c, d, g, h) or 200× (ef).